2024/07/18 08:07:19 | |
---|---|
Price | |
0.4845 EUR | |
Difference | 0.00% (0.00) |
ISIN | NL0014040206 |
Symbol | CNTG |
Exchange | Munich |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 14 EUR |
Benchmark | GERMANY DAX |
Bid (Bid size) | 0.4705 EUR (100) |
Ask (Ask size) | 0.504 EUR (100) |
Open | 0.4845 EUR |
High | 0.4845 EUR |
Low | 0.4845 EUR |
Close (prev. day) | 0.4845 EUR |
VWAP | 0.33 EUR |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 1 |
Last size | 0 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/07/12 | Global Equity Ratings | ||
2024/06/21 | Global Equity Ratings | ||
2024/06/14 | Global Equity Ratings | ||
2024/05/29 | Global Equity Ratings | ||
2024/04/26 | Global Equity Ratings |
2024/07/18 08:07:19 | |
---|---|
Price | |
0.4845 EUR | |
Difference | 0.00% (0.00) |
ISIN | NL0014040206 |
Symbol | CNTG |
Exchange | Munich |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 14 EUR |
Benchmark | GERMANY DAX |
Bid (Bid size) | 0.4705 EUR (100) |
Ask (Ask size) | 0.504 EUR (100) |
Open | 0.4845 EUR |
High | 0.4845 EUR |
Low | 0.4845 EUR |
Close (prev. day) | 0.4845 EUR |
VWAP | 0.33 EUR |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 1 |
Last size | 0 |
6m | 1Y | 3Y | |
Perf (%) | -55.14% | -64.11% | -94.75% |
Perf (abs.) | -0.60 | -0.87 | -8.74 |
Beta | 0.70 | 0.67 | 0.72 |
Volatility | 82.59 | 76.06 | 93.84 |
Ø price 5 days | Ø volume 5 days (pcs.) | 0.4592 EUR (0) |
Ø price 30 days | Ø volume 30 days (pcs.) | 0.3865 EUR (0) |
Ø price 100 days | Ø volume 100 days (pcs.) | 0.4822 EUR (209) |
Ø price 250 days | Ø volume 250 days (pcs.) | 0.8200 EUR (89) |
YTD High | date | 1.1350 EUR (2024/01/18) |
YTD Low | date | 0.3300 EUR (2024/06/03) |
52 Weeks High | date | 1.4450 EUR (2023/12/13) |
52 Weeks Low | date | 0.3300 EUR (2024/06/03) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Tradegate | 2024/07/17 | 22:26 | 0.4905 EUR | 0.00 | 3 |
Stuttgart | 2024/07/18 | 08:00 | 0.4355 EUR | 0.00 | 1 |
Nasdaq | 2024/07/17 | 22:30 | 0.53 USD | 0.01 | 63 |
Munich | 2024/07/18 | 08:07 | 0.4845 EUR | 0.00 | 1 |
Hamburg | 2024/07/18 | 08:16 | 0.4755 EUR | 0.00 | 1 |
Frankfurt | 2024/07/17 | 09:10 | 0.4805 EUR | 0.00 | 2 |
Duesseldorf | 2024/07/18 | 08:10 | 0.47 EUR | 0.00 | 1 |
Berlin | 2024/07/18 | 08:10 | 0.487 EUR | 0.00 | 1 |
CENTOGENE NV |
- - |
Am Strande 7 - 18055 Rostock |
Telefon: +49-381-80113400 |
Fax: +381-80113401 |
E-mail: - |
Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. It operates through the following segments: Pharmaceutical, Diagnostics, and Corporate. The Pharmaceutical segment provides solutions to pharmaceutical partners, including target discovery, early patient recruitment and identification, epidemiological insights, and biomarker discovery. The Diagnostics segment offers genetic sequencing and diagnostics services to clients, who are typically physicians, laboratories, or hospitals, either directly or through distributors. The Other segment covers COVID-19 testing services to clients. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark. |
Kim Stratton | Chairman of Managing Board |
Ian Rentsch | Member of Executive Committee |
Miguel Coego Rios | Member of Executive Committee |
Peter Bauer | Member of Executive Committee |
Peer Schatz | Chairman of Supervisory Board |
Eric Souêtre | Member of Supervisory Board |
Hubert Birner | Member of Supervisory Board |
Jonathan Sheldon | Member of Supervisory Board |
Guido Prehn | Member of Supervisory Board |
Mary Sheahan | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Erste Group Bank AG or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites”) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions (the “Interested Party“).
The publication and distribution of information as well as offering and selling of products and services described on the Websites is prohibited by law in some jurisdictions. For this reason, persons in countries in which the publication as well as the offering and selling of products and services described on the Websites are not permitted by law, must not enter the Websites and/or acquire the products displayed on the Websites.
Neither Erste Group nor any third party shall offer access to the Websites or offer the products to especially, but not limited to citizen/residents of the United States and “U.S. person” (as defined in Regulation S under the US Securities Act 1933 as amended), citizen/resident of Australia, Canada, Great Britain and Japan. For this reason, the distribution or redistribution of the information, materials and products into United States, Australia, Canada, Great Britain and Japan or into any other jurisdiction where it is not permitted under the applicable law, as well as to the citizens/residents of these countries shall be prohibited.
The securities displayed on the Websites have not been and will not be registered under the US Securities Act of 1933 and trading in the securities has not been approved for purposes of the US Commodities Exchange Act of 1936. For this reason the securities may, inter alia, not be offered, sold or delivered within the United States or, for the account and benefit of U.S. persons.
The Interested Party is solely responsible to examine, whether he may enter the Websites under the law applicable to it. Erste Group shall not be responsible for the distribution of content of any of the Websites to individuals or entities which provide false information about their right to enter the Websites. For this reason Erste Group shall not be liable for any legal claims or damages which may result from the unauthorized entering or reading of the Websites.
By agreeing to this hereto, the Interested Party confirms that
(i) It has read, understood and accepted this Information and the Disclaimer;
(ii) It informed itself about any possible legal restriction and warrants that it is not restricted or prohibited to enter the Websites according to any law applicable; and
(iii) It does not make available the contents of the Websites to any person who is not qualified by law to enter the Websites.
(iV) It is no consumer.